T0070907

T0070907 is a potent and selective PPARγ antagonist. With an apparent binding affinity of 1 nM, this compound covalently modifies PPARγ on cysteine 313 in helix 3 of human PPARγ2. It blocks PPARγ function in both cell-based reporter gene and adipocyte differentiation assays. Consistent with its role as an antagonist of PPARγ, this chemical blocks agonist-induced recruitment of coactivator-derived peptides to PPARγ in a homogeneous time-resolved fluorescence-based assay and promotes recruitment of the transcriptional corepressor NCoR to PPARγ in both glutathione S-transferase pull-down assays and a PPARγ/retinoid X receptor (RXR) α-dependent gel shift assay. Studies with mutant receptors suggest that it modulates the interaction of PPARγ with these cofactor proteins by affecting the conformation of helix 12 of the PPARγ ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARγ/RXRα heterodimer can be almost completely reversed by the simultaneous treatment with RXRα agonist LGD1069, this compound treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARγ/RXRα heterodimer. [1] This chemical treatment inhibits proliferation, invasion and migration but does not significantly affect apoptosis. Molecular inhibition using a dominant negative (Δ462) receptor yields similar results. It also mediates a dose-dependent decrease in phosphorylation of PPARγ, and its ability to bind to DNA, and may directly affect mitogen-activated protein kinase signaling. [2]

Lipopolysaccharide preconditioning significantly attenuates the development of renal dysfunction, hepatocellular injury, and circulatory failure as well as the increase in the plasma levels of interleukin-1 [beta] caused by severe endotoxemia. This compound can attenuate all of these beneficial effects afforded by preconditioning with lipopolysaccharide [3]

• Saggio di legame del ligando

  Per determinare l'affinità di legame di T0070907 ai PPAR, viene eseguito un saggio di prossimità a scintillazione (SPA) con le seguenti modifiche. Una reazione di 90 μl contiene tampone SPA (10 mM KH₂PO₄, 10 mM KH₂PO₄, 2 mM EDTA, 50 mM NaCl, 1 mM ditiotreitolo, 2 mM CHAPS, 10% (v/v) glicerolo, pH 7.1), 50 ng di GST-PPARγ (o 150 ng di GST-PPARα, GST-PPARδ), 5 nM di radioligandi marcati con ³H e 5 μl di questo composto in Me₂SO. Dopo incubazione per 1 ora a temperatura ambiente, vengono aggiunti 10 μl di microsfere SPA rivestite di polilisina (a 20 mg/ml in tampone SPA) e la miscela viene incubata per 1 ora prima della lettura in Packard Topcount.

• Linee cellulari

  MCF-7 cells

• Concentrazioni

  20 μM and higher concentrations

• Tempo di incubazione

  48 h

• Metodo

  MTS assay

• Modelli animali

  Preconditioning is performed by administering a low dose (1 mg/kg) of Escherichia coli LPS (serotype 0.127:B8) intraperitoneally 24 hr before the induction of severe endotoxemia.

• Dosaggi

  1 mg/kg

• Somministrazione

  intraperitoneally